Cyclo Therapeutics (CYTH) and Its Peers Head-To-Head Contrast

Cyclo Therapeutics (NASDAQ:CYTHGet Rating) is one of 41 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it compare to its competitors? We will compare Cyclo Therapeutics to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.


This table compares Cyclo Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cyclo Therapeutics -900.76% -117.23% -90.70%
Cyclo Therapeutics Competitors -435.63% -59.61% -0.06%

Earnings & Valuation

This table compares Cyclo Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cyclo Therapeutics $1.59 million -$14.29 million -1.22
Cyclo Therapeutics Competitors $4.57 billion $425.65 million 6.65

Cyclo Therapeutics’ competitors have higher revenue and earnings than Cyclo Therapeutics. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Cyclo Therapeutics has a beta of -0.93, meaning that its share price is 193% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics’ competitors have a beta of -129.53, meaning that their average share price is 13,053% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Cyclo Therapeutics and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclo Therapeutics 0 0 1 0 3.00
Cyclo Therapeutics Competitors 272 1015 1294 40 2.42

Cyclo Therapeutics presently has a consensus target price of $16.00, indicating a potential upside of 479.71%. As a group, “Industrial organic chemicals” companies have a potential upside of 20.38%. Given Cyclo Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Cyclo Therapeutics is more favorable than its competitors.

Insider and Institutional Ownership

5.2% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 49.9% of shares of all “Industrial organic chemicals” companies are held by institutional investors. 12.3% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 11.6% of shares of all “Industrial organic chemicals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Cyclo Therapeutics competitors beat Cyclo Therapeutics on 8 of the 13 factors compared.

Cyclo Therapeutics Company Profile (Get Rating)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with's FREE daily email newsletter.